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We investigated the eﬀect of traditional risk factors (hypertension, dyslipidemia and smoking) on the association between
angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and peripheral arterial disease (PAD) in 945
(454 men and 491 women) Taiwanese type 2 diabetic patients with a mean age of 63.5 (SD: 11.4) years. Among them, 81 (31 men
and 50 women) had PAD (ankle-brachial index <0.9). The adjusted odds ratios (95% conﬁdence intervals) were 2.48 (1.18–5.21),
1.69 (1.00–2.85) and 1.64 (1.12–2.39), respectively, for recessive (DD versus II + ID), dominant (DD + ID versus II) and additive
(II = 0, ID = 1a n dD D= 2) models. While analyzing the interaction between DD and the individual risk factor of hypertension,
smokinganddyslipidemia,patientswiththeriskfactorandwithDDhadthehighestriskcomparedtoreferentpatientswithoutthe
risk factor and with II/ID. The respective adjusted odds ratios were 5.41 (2.05–14.31), 7.38 (1.87–29.06) and 4.64 (1.70–12.64). We
did not ﬁnd a signiﬁcant interaction between DD and any of the risk factors under multiplicative or additive scale. In conclusion,
traditionalriskfactors(hypertension,smokinganddyslipidemia)playanimportantroleintheassociationbetweenACEgenotypes
and PAD. Patients with DD genotype and traditional risk factors are at the highest risk.
1.Introduction
Angiotensin-converting enzyme (ACE) converts angiotensin
I to angiotensin II and degrades bradykinin [1]. Its activity is
genetically determined by an insertion/deletion (I/D) poly-
morphism [2]. Individuals with DD genotype, a marker
for diabetic nephropathy [1], hypertension [1], renal artery
stenosis [3], cardiomyopathies [1], and coronary and carotid
atherosclerosis [1], have a twofold increase in ACE concen-
tration [2]. However, its potential as a risk factor for periph-
eral arterial disease (PAD) is rarely studied.
Smoking plays an important role in mediating the asso-
ciation between ACE polymorphism and the intima media
thickness of the carotid arteries [4], coronary atheroscle-
rosis [5], and cardiovascular mortality [6]. A meta-analysis
conﬁrmed the association between DD and carotid intima
media thickness, which was more prominent in high-risk
populations [7]. These observations supported the impor-
tance of traditional risk factors together with ACE gene
on cardiovascular disease. However, studies simultaneously
evaluating the eﬀects of traditional risk factors including
hypertension, dyslipidemia, and smoking on the association
between the ACE genotypes and PAD are still lacking. The
present study assessed the interaction between these risk
factors and DD genotype on PAD risk in Taiwanese patients
with type 2 diabetes mellitus.2 Experimental Diabetes Research
2.MaterialsandMethods
2.1. Subjects. The study was approved by an ethics commit-
tee,andallsubjectsparticipatedwiththeirinformedconsent.
A total of 945 (454 men and 491 women) diabetic patients
were recruited consecutively from the outpatient clinics of a
medical center in Taiwan. The mean age was 63.5 (SD: 11.4)
years. To avoid recruitment of patients with type 1 diabetes
mellitus, the patients must be treated with oral antidiabetic
drugs or insulin, and they must not have received insulin
treatment within one year of diabetes diagnosis, nor showed
diabetic ketoacidosis at disease onset. We chose type 2
diabetic patients for the study because the prevalence of PAD
islowinthegeneralpopulation.Eveninthehighriskdiabetic
patients, the prevalenceof PAD is only approximately 10% in
our population [8].
2.2. Diagnosis of PAD. Diagnosis of PAD was based on an
ankle-brachial index (ABI) <0.9 on either side of the low-
er extremities as described in our previous studies [8–
10]. Doppler ultrasound (Medacord PVL, MedaSonic Inc.,
Mountain View, Calif, USA) was used to measure the systolic
blood pressure on bilateral brachial, posterior tibial and
dorsal pedal arteries on a supine position after a 20-minute
rest. The occluding cuﬀs( 5 5c m× 12.5cm) were applied just
above the malleoli for measurement of ankle pressures. The
Doppler probe used was 8MHz in frequency. Right and left
ABI were calculated automatically by the device by dividing
the higher pressure on the dorsal pedal or posterior tibial
arteries on right and left sides, respectively, by the higher
brachial pressure on either side.
2.3. Determination of Risk Factors and Covariates. Smoking,
hypertension, and dyslipidemia were investigated for their
interaction with ACE genotypes. Uric acid [8]a n dl i p o p r o -
tein (a) [9] have been identiﬁed as signiﬁcant predictors for
PAD in our diabetic patients. Therefore, the confounders
included age, sex, body mass index, duration of diabetes,
hemoglobin A1c, uric acid, and lipoprotein (a).
Ever smokers (n=333) were deﬁned as those who
smoked one or more cigarettes per day. Patients who did
not smoke were deﬁned as never smokers (n=611). Blood
pressure was measured on the right arm after 20min rest on
a sitting position with a mercury sphygmomanometer. The
ﬁrst perception of successive sounds was taken as systolic
blood pressure and the complete disappearance of sound
(KorotkoﬀphaseV)asdiastolicbloodpressure.Patientswere
deﬁned as having hypertension if undergoing antihyperten-
sive treatments, having systolic blood pressure ≥140mmHg,
or showing diastolic blood pressure ≥90mmHg.
Total cholesterol, triglycerides, high- and low-density
lipoprotein cholesterol, uric acid, lipoprotein (a), and he-
moglobin A1c were determined [8–10]. Dyslipidemia was
deﬁned as triglycerides ≥150mg/dL and/or high-density li-
poprotein cholesterol <35mg/dL for men or <39mg/dL
for women, and/or total cholesterol ≥200mg/dL, and/or
low-density lipoprotein cholesterol ≥100mg/dL, or those
undergoing treatment for lipid disorder [11].
Duration of diabetes was deﬁned as the time period in
years between the time being recruited into the study and the
time diabetes was diagnosed. Body weight and body height
were measured with light clothes and bare feet. Body mass
index was calculated as body weight in kilograms divided by
the square of body height in meters.
2.4. Genomic DNA Preparation and ACE Genotyping. Ge-
nomic DNA was extracted from peripheral blood, and the
genotyping of the ACE gene was performed as described
previously [12]. Brieﬂy, the extracted DNA was subject to
polymerase chain reaction (PCR) using sense oligo 5 -CTG-
GAGACCACTCCCATCCTTTCT-3  and antisense oligo 5 -
GATGTCGCCATCACATTCGTCAGAT-3  as primers in
a solution containing 1.5mmol/L MgCl2, 50mmol/L KCl,
10mmol/L Tris-HCl, 0.1% (w/v) gelatin, 1% Triton X-100,
0.3mmol/L each of dNTP (ProTech), and 2 units Pro Taq
D N Ap o l y m e r a s e( P r o T e c h ) ,w i t hp H9 . 0 .A p p r o x i m a t e l y
500ng to 1µg of genomic DNA was used per reaction. The
PCR cycling was performed with initial denaturation at 94◦C
for 3min followed by 35 cycles of 94◦C for 1min, 58◦Cf o r
1min, 72◦C for 2min, and then by a ﬁnal extension period
at 72◦C for 7min. The PCR products were either 490 base
pairs (bps) (insertion allele) or 190bps (deletion allele). The
D allele is preferentially ampliﬁed in heterozygotes giving
rise to mistyping of ID as DD in approximately 5% of
cases [13]. To avoid such mistyping, samples of DD geno-
type were subject to a second independent PCR with primers
that recognize an insertion-speciﬁc sequence: 5 -TGGGA-
CCACAGCGCCCGCCACTAC-3  as sense and 5 -TCG-
CCAGCCCTCCCATGCCCATAA-3  as antisense primers.
The PCR reaction yields a 335bp DNA product in the pres-
e n c eo ft h eIa l l e l e[ 13].
2.5.StatisticalAnalyses. ThePCversionofStatisticalPackage
for Social Sciences (SPSS 10.0, Chicago, Ill, USA) was
used. Data were expressed as means (SD) and case num-
ber (percentages). Triglycerides and lipoprotein (a) were
logarithmically transformed due to skewness. P<0.05
was considered statistically signiﬁcant. Deviations from the
Hardy-Weinberg equilibrium were assessed with chi-square
test. Student’s t-test or one-way ANOVA and chi-square test
were used to compare the diﬀerences of the continuous and
categorical variables including the diﬀerences among the
ACE genotypes, respectively.
The following gene transmission models were consid-
e r e d :( 1 )ar e c e s s i v ee ﬀect (DD versus ID + II), (2) a dom-
inant eﬀect (DD + ID versus II), and (3) an additive eﬀect
(assigning 0, 1, and 2 for II, ID, and DD, respectively) of
the D allele. The association was evaluated by chi-square
test followed by logistic regression after adjustment for age,
sex, body mass index, duration of diabetes, hemoglobin
A1c, uric acid, ln[lipoprotein (a)], hypertension, smoking,
and dyslipidemia. The Akaike information criterion (AIC
= −2 × model log-likelihood + 2 × number of model
parameters) was computed, and the model with lowest AIC
was considered the best ﬁt. Models diﬀering in AIC by <2
units were considered indistinguishable [14].Experimental Diabetes Research 3
Table 1: Comparisons of characteristics of study subjects with and without peripheral arterial disease.
Characteristics
Peripheral arterial disease
P
Yes No
n 81 864
Age, years 72.9 (7.3) 62.6 (11.3) <0.001
Sex
Men 31 (38.3) 423 (49.0) 0.066
Women 50 (61.7) 441 (51.0)
Duration of diabetes, years 16.3 (9.3) 10.8 (7.7) <0.001
Body mass index, kg/m2 23.6 (3.3) 24.9 (3.4) 0.001
Smoking
Never smokers 51 (63.0) 560 (64.9) >0.1
Current or former smokers 30 (37.0) 303 (35.1)
Hypertension
No 17 (21.0) 369 (42.7) <0.001
Yes 64 (79.0) 495 (57.3)
Systolic blood pressure, mmHg 146.0 (18.2) 134.0 (17.3) <0.001
Diastolic blood pressure, mmHg 82.9 (12.0) 83.4 (9.6) >0.1
Hemoglobin A1c, % 7.9 (1.6) 7.9 (1.9) >0.1
Dyslipidemia
No 18 (22.2) 316 (36.6) 0.010
Yes 63 (77.8) 548 (63.4)
Total cholesterol, mg/dL 209.7 (42.2) 205.1 (43.3) >0.1
Ln(triglycerides), mg/dL 5.1 (0.6) 5.0 (0.6) 0.03
High-density lipoprotein cholesterol, mg/dL 46.8 (12.7) 48.1 (13.6) >0.1
Low-density lipoprotein cholesterol, mg/dL 115.5 (34.9) 114.2 (33.8) >0.1
Ln[lipoprotein (a)], mg/dL 5.0 (1.2) 4.7 (1.1) 0.011
Uric acid, mg/dL 5.9 (2.2) 5.2 (2.0) 0.006
Angiotensin-converting enzyme genotype
II 35 (43.2) 430 (49.8) >0.1
ID 34 (42.0) 358 (41.4)
DD 12 (14.8) 76 (8.8)
Allele frequency
I 104 (64.2) 1,218 (70.5) >0.1
D 58 (35.8) 510 (29.5)
Data are expressed as mean (SD) or n (percentage).
To assess the interaction between risk factor and DD,
the two-by-four table [15] and the synergy indices of mul-
tiplicativity (SIM) and additivity (SIA) [16] were applied.
The patients were divided into 4 subgroups: (A) without
risk factor (hypertension, smoking, or dyslipidemia) and
without DD as referent group; (B) without risk factor but
with DD, (C) with risk factor but without DD, and (D)
with risk factor and with DD. Multiple logistic regression
was used to estimate the adjusted odds ratios for PAD
among the 4 subgroups (treated as a categorical variable
in the model) using patients without the risk factor and
without DD as referent. These models were created after ad-
justment for age, sex, body mass index, duration of diabetes,
hemoglobin A1c, uric acid, ln[lipoprotein (a)], and the
two risk factors other than the one used for classifying
the patients (e.g., in the models classifying the patients
according to hypertension and ACE genotypes, smoking and
dyslipidemia were additionally adjusted). Additional logistic
regression was performed to calculate the synergy indices by
entering the covariates, the risk factors, the ACE genotype,
and the product term of risk factors (one at a time) and ACE
genotypeasindependentvariables.SIMwastheoddsratioof
the product term. SIA was computed according to Zou [16].
3. Results
The allele frequencies for I and D were 69.9% and 30.1%,
respectively. The frequencies of II, ID, and DD were 49.0%,
41.9%, and 9.1%, respectively, with the distribution in
the Hardy-Weinberg equilibrium. The case number for
those without any risk factors of smoking, hypertension, or
dyslipidemia was 101; with only one risk factor was 58, 119,4 Experimental Diabetes Research
Table 2: Comparisons of characteristics by insertion/deletion (I/D) polymorphism of angiotensin-converting enzyme genotypes.
Characteristics
Angiotensin-converting enzyme genotype
II ID DD
n (%) 465 392 88
Age, years 64.1 (11.7) 62.8 (11.2) 63.4 (11.0)
Sex
Men 219 (47.1) 192 (49.0) 43 (48.9)
Women 246 (52.9) 200 (51.0) 45 (51.1)
Duration of diabetes, years 11.8 (8.2) 10.7 (7.9) 10.8 (7.6)
Body mass index, kg/m2 24.8 (3.6) 24.8 (3.3) 25.0 (3.6)
Smoking
Never smokers 309 (66.6) 244 (62.2) 58 (65.9)
Current or former smokers 155 (33.4) 148 (37.8) 30 (34.1)
Hypertension
No 191 (41.1) 158 (40.3) 37 (42.0)
Yes 274 (58.9) 234 (59.7) 51 (58.0)
Systolic blood pressure, mmHg 135.8 (18.1) 133.9 (16.6) 135.5 (19.5)
Diastolic blood pressure, mmHg 83.3 (9.9) 83.2 (9.5) 84.3 (10.7)
Hemoglobin A1c, % 7.8 (1.8) 7.9 (1.9) 8.2 (1.9)
Dyslipidemia
No 167 (35.9) 132 (33.7) 35 (39.8)
Yes 298 (64.1) 260 (66.3) 53 (60.2)
Total cholesterol, mg/dL 204.3 (43.1) 208.3 (43.8) 199.5 (40.3)
Ln(triglycerides), mg/dL 5.0 (0.6) 5.0 (0.6) 4.9 (0.6)
High-density lipoprotein cholesterol, mg/dL 47.4 (13.5) 48.9 (13.6) 46.7 (12.9)
Low-density lipoprotein cholesterol, mg/dL 114.1 (34.7) 115.4 (34.2) 110.5 (27.6)
Ln[lipoprotein (a)], mg/dL 4.7 (1.2) 4.7 (1.1) 4.6 (1.2)
Uric acid, mg/dL 5.2 (2.1) 5.3 (1.9) 5.3 (2.1)
Peripheral arterial disease
No 430 (92.5) 358 (91.3) 76 (86.4)
Yes 35 (7.5) 34 (8.7) 12 (13.6)
Data are expressed as mean (SD) or n (percentage).
None of the above comparisons among the genotypes was statistically signiﬁcant (i.e., all P>0.05).
and 131, respectively; with two risk factors of smoking and
hypertension, smoking and dyslipidemia, or hypertension
and dyslipidemia was 55, 95, and 260, respectively; with all
threeriskfactorswas125(smokingnotavailableinonecase).
Table 1 compares the characteristics of patients with and
without PAD. Age, duration of diabetes, body mass index,
hypertension, systolic blood pressure, dyslipidemia, ln(tri-
glycerides), ln[lipoprotein (a)], and uric acid were signiﬁ-
cantly diﬀerent, but DD genotype and D allele frequencies
were not.
Table 2 compares the characteristics by genotypes. Even
though the point estimate for PAD prevalence in those with
DD was higher, the prevalence did not diﬀer signiﬁcantly
from that in the II and ID group.
Table 3 shows the gene transmission models. In chi-
square test, none were signiﬁcant. However, the adjusted
oddsratiosforrecessiveandadditivemodelsweresigniﬁcant,
while that for the dominant model was borderline signiﬁcant
with P value of 0.050. AIC was lowest for the additive model
in the adjusted regressions. However, the adjusted additive
and recessive models were indistinguishable because they
diﬀered in AIC by <2 units.
Table 4 shows the gene-environment interactions. In the
multiple logistic regression models with patient categoriza-
tion based on two-by-four table, the subgroups with the
risk factor and DD showed the highest risk; the subgroups
without the risk factor but with DD were not signiﬁcantly
diﬀerent from the referents. All SIMs and SIAs did not diﬀer
from unity and suggested a lack of interaction on either the
multiplicative or the additive scale.
4. Discussion
This is probably the ﬁrst study evaluating the interaction
between individual risk factor of hypertension, smoking, or
dyslipidemia and the ACE DD genotype on the risk of PAD
by classifying the patients using the two-by-four table and by
usingthesynergyindicesforevaluationofgene-environmentExperimental Diabetes Research 5
Table 3:Genetransmissionmodelsforinsertion/deletion(I/D)polymorphismofangiotensin-convertingenzymegeneonperipheralarterial
disease.
chi-square test Logistic regression∗
Gene transmission Total N Peripheral arterial disease, n (%) P value
Adjusted odds ratio
(95% conﬁdence
interval)
P value
Akaike
information
criterion
No Yes
Recessive model
II/ID 857 788 (91.9) 69 (8.1) 1.00
DD 88 76 (86.4) 12 (13.6) 0.075 2.48 (1.18–5.21) 0.017 425.880
Dominant model
II 465 430 (92.5) 35 (7.5) 1.00
ID/DD 480 434 (90.4) 46 (9.6) 0.259 1.69 (1.00–2.85) 0.050 427.157
Additive model
II = 0, 465 430 (92.5) 35 (7.5) 1.00
ID = 1, 392 358 (91.3) 34 (8.7) 1.64 (1.12–2.39) per risk
DD = 2 88 76 (86.4) 12 (13.6) 0.171 allele 0.010 424.612
∗Adjusted variables include age, sex, body mass index, duration of diabetes, hemoglobin A1c, uric acid, ln[lipoprotein (a)], hypertension, smoking, and
dyslipidemia.
Table 4: Gene-environment models evaluating the interaction between insertion/deletion (I/D) polymorphism of angiotensin-converting
enzyme (ACE) genotypes and traditional risk factors including hypertension, smoking, and dyslipidemia in peripheral arterial disease.
Risk factor
ACE
genotype Total N Peripheral arterial disease, n (%)
Adjusted odds
ratio
(95% conﬁdence
interval)
P-value Synergy index of
multiplicativity
Synergy index
of additivity
No Yes
Hypertension
No II/ID 349 334 15 1.00 1.23 (0.19–8.01) 2.01 (0.32–12.8)
DD 37 35 2 2.10 (0.40–11.17) 0.383
Yes II/ID 508 454 54 2.09 (1.07–4.07) 0.030
DD 51 41 10 5.41 (2.05–14.31) 0.001
Smoking
Never smokers II/ID 553 510 43 1.00 1.21 (0.25–5.87) 2.16 (0.43–10.80)
DD 58 50 8 2.33 (0.94–5.81) 0.069
Ever smokers II/ID 303 277 26 2.63 (1.16–5.96) 0.021
DD 30 26 4 7.38 (1.87–29.06) 0.004
Dyslipidemia
No II/ID 299 284 15 1.00 1.21 (0.23–6.37) 1.88 (0.29–12.04)
DD 35 32 3 2.16 (0.53–8.90) 0.285
Yes II/ID 558 504 54 1.77 (0.92–3.43) 0.088
DD 53 44 9 4.64 (1.70–12.64) 0.003
interaction. We demonstrated that the predisposition of DD
to PAD was greatest in the presence of risk factors including
hypertension, smoking, or dyslipidemia, and observed that
there was no signiﬁcant interaction on the scale of either
additivity or multiplicativity.
IncontrasttoastrongerassociationbetweenDDanddis-
ease in low-risk subjects [17] or a lack of such a subgroup as-
sociation [18], this study strongly suggested that PAD risk
increasedsigniﬁcantlyinthepresenceofbothtraditionalrisk
factors and DD. Two decades ago, Khoury et al. asserted
that failure to consider the eﬀect of environmental factors
can result in an estimation of the relative risk close to unity
implying no genetic eﬀect even if there is a strong gene-
environment eﬀect [19]. Accordingly we did not observe
a signiﬁcant association between DD and PAD in crude
analyses (Tables 1 and 2). However, when the combination
eﬀects of traditional risk factors and DD genotype were
considered, PAD risk increased signiﬁcantly (Table 4). Our6 Experimental Diabetes Research
present study can be viewed as a case study supporting the
assertion made by Khoury et al. [19].
Studies with smaller sample sizes tended to report larger
odds ratios [18]. One reason is that the cases were more
correctly diagnosed and the controls better selected in small-
er studies. Other explanations include publication bias and
occurrence by chance. The larger odds ratios in our study
might be due to selection bias resulting from a hospital-
based design, the smaller sample sizes in the subgroups
with DD and PAD, the more accurate diagnosis of PAD
with the Doppler ultrasound or the more accurate genotyp-
ingbyconﬁrmatoryPCR.Becausethegenotypedistributions
were in the Hardy-Weinberg equilibrium, the possibility of
selection bias was reduced. Due to the small sample size in
the subgroups with DD and PAD, we were unable to eval-
uate with suﬃcient statistical power the simultaneous inter-
actions among multiple risk factors and DD by dividing
the subjects into more subgroups. We also recognized that
diabetes mellitus is a risk factor and all subjects were having
at least this one risk factor, even in the referent groups.
Therefore our ﬁndings should be reconﬁrmed and the joint
eﬀects of multiple risk factors should be evaluated by future
population-based studies with larger sample sizes collected
ideally in a prospective fashion.
Based on the following reasons we believed that the as-
sociation is not spurious. First, the strength of association
was strong and consistent. Second, a Bonferroni’s correction
for 12 tests still yielded signiﬁcant P values for patients with
DD and the risk factor (Table 4). Third, the results were
not inﬂuenced if the models were adjusted for the following
additionalconfoundersoneatatime:smokinginpack-years,
use of antihypertensive agents, number of antihypertensive
agents used (as a proxy for the severity of hypertension), and
use of lipid-lowering agents (data not shown).
Although we have additionally analyzed the use of anti-
hypertensive and lipid-lowering drugs in secondary analyses,
we still could not completely exclude the possible residual
confounding eﬀects of medications used by the patients over
time which might not have been captured at the time of the
study. Furthermore, the eﬀects of many risk factors might
be cumulative over time and the lack of their analyses as
time varying variables was a possible limitation. A residual
confounding by the severity of diabetes might also be a con-
cern because, though not statistically signiﬁcant, patients
with DD had a higher hemoglobin A1c (Table 2). The
numberofpatientswithPAD(n=81)incomparisontothose
withoutPAD(n=864)reﬂectedtheprevalenceofPADinthis
cohort of diabetic patients. The PAD prevalence of 8.6% in
this study is in line with earlier studies conducted in Taiwan
[8–10]. However, the relatively small number of PAD cases
may indicate that the study was underpowered. Another
limitation of the study was that we did not measure ACE lev-
els for the patients and could not evaluate the association
among PAD risk, DD genotype, and ACE level.
In summary, Taiwanese patients with type 2 diabetes
mellitus who simultaneously carry the DD genotype and
possess the individual risk factors of hypertension, smoking
or dyslipidemia are at especially high risk of PAD.
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